Maternal zidovudine/lamivudine/lopinavir-ritonavir — Competitive Intelligence Brief

Maternal zidovudine/lamivudine/lopinavir-ritonavir (Maternal zidovudine/lamivudine/lopinavir-ritonavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + protease inhibitor). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NRTI + protease inhibitor) HIV reverse transcriptase, HIV protease Infectious Disease / Virology Small molecule

Target snapshot

Maternal zidovudine/lamivudine/lopinavir-ritonavir (Maternal zidovudine/lamivudine/lopinavir-ritonavir) — Centers for Disease Control and Prevention. This combination of antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication in pregnant women and prevent mother-to-child transmission.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Maternal zidovudine/lamivudine/lopinavir-ritonavir TARGET	Maternal zidovudine/lamivudine/lopinavir-ritonavir	Centers for Disease Control and Prevention	phase 3	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase, HIV protease
tenofovir + emtricitabine + atazanavir-ritonavir	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease
emtricitabine, darunavir/cobicistat, maraviroc	emtricitabine, darunavir/cobicistat, maraviroc	Giovanni Di Perri	marketed	Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist)	HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor
tenofovir + abacavir + lopinavir/ritonavir	tenofovir + abacavir + lopinavir/ritonavir	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI/boosted)	HIV reverse transcriptase, HIV protease
Rilpivirine + darunavir/cobicistat	Rilpivirine + darunavir/cobicistat	A.O. Ospedale Papa Giovanni XXIII	marketed	Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster)	HIV reverse transcriptase, HIV protease
Highly active antiretroviral therapy	Highly active antiretroviral therapy	PETHEMA Foundation	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)
All licensed antiretroviral medications	All licensed antiretroviral medications	University of Minnesota	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + protease inhibitor) class)

1. Hospital Clinic of Barcelona · 2 drugs in this class
2. Centers for Disease Control and Prevention · 1 drug in this class